Two HER2-targeted ADCs—T-DM1 and T-DXd—were found to eradicate EMPD tumors in two weeks (Figure 2), in contrast to trastuzumab monotherapy, which is found to only suppress tumor growth [31]. The gene discussed is ERBB2; the disease is neoplasm.